Trial Outcomes & Findings for Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (NCT NCT02287311)
NCT ID: NCT02287311
Last Updated: 2025-02-24
Results Overview
To evaluate the safety of administering escalating doses of banked allogeneic, partially HLA-matched rapid EBV specific T cells.
Recruitment status
ACTIVE_NOT_RECRUITING
Study phase
PHASE1
Target enrollment
38 participants
Primary outcome timeframe
8 weeks
Results posted on
2025-02-24
Participant Flow
Of the 38 enrolled participants, 2 were screened but did not receive EBV Specific T cell (EST) infusions as they opted for alternate treatment while 36 participants received at least one EST infusion across three treatment groups (A, B and C), with each group having three dose levels. One of the treated participants who was not evaluable for DLT and response, and later re-enrolled was counted as 2 individual participants for the purpose of reporting.
Participant milestones
| Measure |
Group A Cohort 1
Group A: Participants with 1st or subsequent relapse.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group A Cohort 2
Group A: Participants with 1st or subsequent relapse.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group A Cohort 3
Group A: Participants with 1st or subsequent relapse.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group B Cohort 1
Group B:Participants with persistent active disease despite therapy.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group B Cohort 2
Group B:Participants with persistent active disease despite therapy.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group B Cohort 3
Group B:Participants with persistent active disease despite therapy.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group C Cohort 1
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group C Cohort 2
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group C Cohort 3
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
|---|---|---|---|---|---|---|---|---|---|
|
Cohort 1: Dose Level 1
STARTED
|
3
|
0
|
0
|
5
|
0
|
0
|
2
|
0
|
0
|
|
Cohort 1: Dose Level 1
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 1: Dose Level 1
NOT COMPLETED
|
3
|
0
|
0
|
5
|
0
|
0
|
2
|
0
|
0
|
|
Cohort 2: Dose Level 2
STARTED
|
0
|
3
|
0
|
0
|
3
|
0
|
0
|
4
|
0
|
|
Cohort 2: Dose Level 2
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
|
Cohort 2: Dose Level 2
NOT COMPLETED
|
0
|
3
|
0
|
0
|
3
|
0
|
0
|
2
|
0
|
|
Cohort 3: Dose Level 3
STARTED
|
0
|
0
|
6
|
0
|
0
|
7
|
0
|
0
|
3
|
|
Cohort 3: Dose Level 3
COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 3: Dose Level 3
NOT COMPLETED
|
0
|
0
|
6
|
0
|
0
|
7
|
0
|
0
|
3
|
Reasons for withdrawal
| Measure |
Group A Cohort 1
Group A: Participants with 1st or subsequent relapse.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group A Cohort 2
Group A: Participants with 1st or subsequent relapse.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group A Cohort 3
Group A: Participants with 1st or subsequent relapse.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group B Cohort 1
Group B:Participants with persistent active disease despite therapy.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group B Cohort 2
Group B:Participants with persistent active disease despite therapy.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group B Cohort 3
Group B:Participants with persistent active disease despite therapy.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group C Cohort 1
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group C Cohort 2
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group C Cohort 3
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
|---|---|---|---|---|---|---|---|---|---|
|
Cohort 1: Dose Level 1
Death
|
2
|
0
|
0
|
3
|
0
|
0
|
1
|
0
|
0
|
|
Cohort 1: Dose Level 1
Lost to Follow-up
|
0
|
0
|
0
|
2
|
0
|
0
|
1
|
0
|
0
|
|
Cohort 1: Dose Level 1
Physician Decision
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 2: Dose Level 2
Death
|
0
|
2
|
0
|
0
|
2
|
0
|
0
|
2
|
0
|
|
Cohort 2: Dose Level 2
Lost to Follow-up
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
Cohort 2: Dose Level 2
Refused follow-up
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Cohort 3: Dose Level 3
Death
|
0
|
0
|
4
|
0
|
0
|
4
|
0
|
0
|
2
|
|
Cohort 3: Dose Level 3
Lost to Follow-up
|
0
|
0
|
2
|
0
|
0
|
2
|
0
|
0
|
0
|
|
Cohort 3: Dose Level 3
On long-term follow-up
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
Baseline Characteristics
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Baseline characteristics by cohort
| Measure |
Group A Cohort 1
n=3 Participants
Group A: Participants with 1st or subsequent relapse.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group A Cohort 2
n=3 Participants
Group A: Participants with 1st or subsequent relapse.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group A Cohort 3
n=6 Participants
Group A: Participants with 1st or subsequent relapse.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group B Cohort 1
n=5 Participants
Group B:Participants with persistent active disease despite therapy.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group B Cohort 2
n=3 Participants
Group B:Participants with persistent active disease despite therapy.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group B Cohort 3
n=7 Participants
Group B:Participants with persistent active disease despite therapy.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group C Cohort 1
n=2 Participants
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group C Cohort 2
n=4 Participants
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group C Cohort 3
n=3 Participants
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Total
n=36 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
15.0 years
n=5 Participants
|
18.0 years
n=7 Participants
|
18.5 years
n=5 Participants
|
54.0 years
n=4 Participants
|
51.0 years
n=21 Participants
|
41.0 years
n=8 Participants
|
36.0 years
n=8 Participants
|
9.5 years
n=24 Participants
|
37.0 years
n=42 Participants
|
19.5 years
n=42 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
1 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
2 Participants
n=42 Participants
|
11 Participants
n=42 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
2 Participants
n=21 Participants
|
6 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
25 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
1 Participants
n=42 Participants
|
5 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
3 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
5 Participants
n=5 Participants
|
5 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
6 Participants
n=8 Participants
|
2 Participants
n=8 Participants
|
2 Participants
n=24 Participants
|
2 Participants
n=42 Participants
|
30 Participants
n=42 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
2 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
4 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
1 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
6 Participants
n=42 Participants
|
|
Race (NIH/OMB)
White
|
2 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
2 Participants
n=5 Participants
|
4 Participants
n=4 Participants
|
3 Participants
n=21 Participants
|
4 Participants
n=8 Participants
|
1 Participants
n=8 Participants
|
3 Participants
n=24 Participants
|
3 Participants
n=42 Participants
|
25 Participants
n=42 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
0 Participants
n=42 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=21 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=8 Participants
|
1 Participants
n=24 Participants
|
0 Participants
n=42 Participants
|
1 Participants
n=42 Participants
|
PRIMARY outcome
Timeframe: 8 weeksPopulation: All DLT evaluable participants were included in the analysis. DLT evaluable refers to participants who received two infusions and either completed the 8 weeks toxicity evaluation period without experiencing a DLT or developed a DLT during this period. Ten participants were not evaluable for DLT and were excluded from the analysis, including one participant who was later re-enrolled and became evaluable for DLT at the 2nd enrollment.
To evaluate the safety of administering escalating doses of banked allogeneic, partially HLA-matched rapid EBV specific T cells.
Outcome measures
| Measure |
Group A Cohort 3
n=4 Participants
Group A: Participants with 1st or subsequent relapse.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group B Cohort 1
n=4 Participants
Group B:Participants with persistent active disease despite therapy.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group B Cohort 2
n=2 Participants
Group B:Participants with persistent active disease despite therapy.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group B Cohort 3
n=4 Participants
Group B:Participants with persistent active disease despite therapy.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group C Cohort 1
n=2 Participants
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group C Cohort 2
n=2 Participants
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group C Cohort 3
n=2 Participants
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group A Cohort 1
n=2 Participants
Group A: Participants with 1st or subsequent relapse.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group A Cohort 2
n=3 Participants
Group A: Participants with 1st or subsequent relapse.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
|---|---|---|---|---|---|---|---|---|---|
|
Number of Participants With a Dose-limiting Toxicity (DLT)
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: 8 weeksPopulation: All response evaluable participants were included in the analysis. Participants who received the first infusion were evaluable for response, except those who received chemotherapy between the first and second infusions. Two participants were not evaluable for response and were excluded from the analysis. The participant who enrolled twice was counted as 2 individuals but was only evaluable for response at the 2nd enrollment.
To measure anti-tumor and anti-viral effects of ESTs
Outcome measures
| Measure |
Group A Cohort 3
n=6 Participants
Group A: Participants with 1st or subsequent relapse.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group B Cohort 1
n=5 Participants
Group B:Participants with persistent active disease despite therapy.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group B Cohort 2
n=3 Participants
Group B:Participants with persistent active disease despite therapy.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group B Cohort 3
n=7 Participants
Group B:Participants with persistent active disease despite therapy.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group C Cohort 1
n=2 Participants
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group C Cohort 2
n=3 Participants
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group C Cohort 3
n=3 Participants
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group A Cohort 1
n=2 Participants
Group A: Participants with 1st or subsequent relapse.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group A Cohort 2
n=3 Participants
Group A: Participants with 1st or subsequent relapse.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
|---|---|---|---|---|---|---|---|---|---|
|
Percent of Patients Whose Best Response is Either Complete Remission or Partial Remission
|
0.0 percentage of participants
Interval 0.0 to 45.9
|
60.0 percentage of participants
Interval 14.7 to 94.7
|
33.3 percentage of participants
Interval 0.8 to 90.6
|
28.6 percentage of participants
Interval 3.7 to 71.0
|
0.0 percentage of participants
Interval 0.0 to 84.2
|
0.0 percentage of participants
Interval 0.0 to 70.8
|
0.0 percentage of participants
Interval 0.0 to 70.8
|
0.0 percentage of participants
Interval 0.0 to 84.2
|
33.3 percentage of participants
Interval 0.8 to 90.6
|
Adverse Events
Group A Cohort 1
Serious events: 1 serious events
Other events: 3 other events
Deaths: 2 deaths
Group A Cohort 2
Serious events: 0 serious events
Other events: 3 other events
Deaths: 2 deaths
Group A Cohort 3
Serious events: 5 serious events
Other events: 6 other events
Deaths: 4 deaths
Group B Cohort 1
Serious events: 3 serious events
Other events: 5 other events
Deaths: 3 deaths
Group B Cohort 2
Serious events: 2 serious events
Other events: 3 other events
Deaths: 2 deaths
Group B Cohort 3
Serious events: 3 serious events
Other events: 7 other events
Deaths: 4 deaths
Group C Cohort 1
Serious events: 0 serious events
Other events: 2 other events
Deaths: 1 deaths
Group C Cohort 2
Serious events: 2 serious events
Other events: 4 other events
Deaths: 2 deaths
Group C Cohort 3
Serious events: 1 serious events
Other events: 3 other events
Deaths: 2 deaths
Serious adverse events
| Measure |
Group A Cohort 1
n=3 participants at risk
Group A: Participants with 1st or subsequent relapse.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group A Cohort 2
n=3 participants at risk
Group A: Participants with 1st or subsequent relapse.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group A Cohort 3
n=6 participants at risk
Group A: Participants with 1st or subsequent relapse.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group B Cohort 1
n=5 participants at risk
Group B:Participants with persistent active disease despite therapy.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group B Cohort 2
n=3 participants at risk
Group B:Participants with persistent active disease despite therapy.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group B Cohort 3
n=7 participants at risk
Group B:Participants with persistent active disease despite therapy.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group C Cohort 1
n=2 participants at risk
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group C Cohort 2
n=4 participants at risk
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group C Cohort 3
n=3 participants at risk
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
|---|---|---|---|---|---|---|---|---|---|
|
Infections and infestations
Skin infection
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Blood and lymphatic system disorders
Anemia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Diarrhea
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Rectal hemorrhage
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Chills
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Edema limbs
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Fatigue
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Fever
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
4/6 • Number of events 4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
2/4 • Number of events 8 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Localized edema
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Multi-organ failure
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Catheter related infection
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Infections and infestations - Other, specify : COVID-19
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Lung infection
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Sepsis
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory, thoracic and mediastinal disorders - Other, specify : major hemoptysis
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Sore throat
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, specify : Redness
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, specify : Swelling
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
Other adverse events
| Measure |
Group A Cohort 1
n=3 participants at risk
Group A: Participants with 1st or subsequent relapse.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group A Cohort 2
n=3 participants at risk
Group A: Participants with 1st or subsequent relapse.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group A Cohort 3
n=6 participants at risk
Group A: Participants with 1st or subsequent relapse.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group B Cohort 1
n=5 participants at risk
Group B:Participants with persistent active disease despite therapy.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group B Cohort 2
n=3 participants at risk
Group B:Participants with persistent active disease despite therapy.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group B Cohort 3
n=7 participants at risk
Group B:Participants with persistent active disease despite therapy.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
Group C Cohort 1
n=2 participants at risk
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 1: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7 cells/m2 and 2x10\^7 cells/m2,14 days apart.
|
Group C Cohort 2
n=4 participants at risk
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 2: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 2x10\^7cells/m2 and 5x10\^7 cells/m2,14 days apart.
|
Group C Cohort 3
n=3 participants at risk
Group C: Participants with active disease if immunosuppressive chemotherapy is contraindicated.
Cohort 3: Participants were administrated EBV Specific T cells (ESTs), consisting of two infusions 5x10\^7 cells/m2 and 1x10\^8 cells/m2
,14 days apart.
|
|---|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Vomiting
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
3/6 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
28.6%
2/7 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Chills
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
2/6 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Edema limbs
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Fatigue
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
4/6 • Number of events 4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
28.6%
2/7 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
2/4 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Fever
|
66.7%
2/3 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
60.0%
3/5 • Number of events 9 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Gait disturbance
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
General disorders and administration site conditions - Other, specify : leg cramps
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Blood and lymphatic system disorders
Anemia
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
2/3 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
4/6 • Number of events 4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
40.0%
2/5 • Number of events 6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
1/2 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
75.0%
3/4 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Blood and lymphatic system disorders
Blood and lymphatic system disorders - Other, specify : Thrombocytopenia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Cardiac disorders
Chest pain - cardiac
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Cardiac disorders
Palpitations
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
100.0%
3/3 • Number of events 5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Ear and labyrinth disorders
Ear and labyrinth disorders - Other, specify : Clot from bleeding
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Eye disorders
Blurred vision
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Eye disorders
Conjunctivitis
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Eye disorders
Eye disorders - Other, specify : burning
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Abdominal pain
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
28.6%
2/7 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
3/6 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Dental caries
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Diarrhea
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
2/6 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Dysphagia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Fecal incontinence
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Flatulence
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Gastrointestinal disorders - Other, specify : Hemorrhoid type bleeding
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Gastrointestinal disorders - Other, specify : sore throat
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Mucositis oral
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Nausea
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
28.6%
2/7 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Hypothermia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Malaise
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
General disorders
Pain
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Immune system disorders
Allergic reaction
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Infections and infestations - Other, specify : RSV
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Infections and infestations - Other, specify : pneumonia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
40.0%
2/5 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Infections and infestations - Other, specify : right 2nd toe
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Infections and infestations - Other, specify : strep throat
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Mucosal infection
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Rhinitis infective
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Sepsis
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Upper respiratory infection
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
1/2 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
Alanine aminotransferase increased
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
1/2 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
2/4 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
Alkaline phosphatase increased
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
Aspartate aminotransferase increased
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
4/6 • Number of events 4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
40.0%
2/5 • Number of events 6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
28.6%
2/7 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
1/2 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
100.0%
4/4 • Number of events 4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
Blood bilirubin increased
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
2/6 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
Creatinine increased
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
2/6 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
60.0%
3/5 • Number of events 4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
Lymphocyte count decreased
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
3/6 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
80.0%
4/5 • Number of events 6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
100.0%
3/3 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
57.1%
4/7 • Number of events 4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
1/2 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
Neutrophil count decreased
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
80.0%
4/5 • Number of events 12 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
28.6%
2/7 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
1/2 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
2/4 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
Platelet count decreased
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
2/4 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Investigations
White blood cell decreased
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
3/6 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
100.0%
5/5 • Number of events 10 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
42.9%
3/7 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
100.0%
2/2 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
2/4 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Anorexia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
4/6 • Number of events 4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
2/4 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hypercalcemia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
3/6 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
60.0%
3/5 • Number of events 4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
1/2 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
2/6 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
1/2 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hypermagnesemia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hypernatremia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
2/6 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
1/2 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
83.3%
5/6 • Number of events 5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
2/4 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
4/6 • Number of events 4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
40.0%
2/5 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
28.6%
2/7 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hypoglycemia
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hypokalemia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
3/6 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
60.0%
3/5 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
42.9%
3/7 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
75.0%
3/4 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hypomagnesemia
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
4/6 • Number of events 4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
40.0%
2/5 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
28.6%
2/7 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
75.0%
3/4 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
40.0%
2/5 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
2/6 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Musculoskeletal and connective tissue disorders
Chest wall pain
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Musculoskeletal and connective tissue disorders
Generalized muscle weakness
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
40.0%
2/5 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Musculoskeletal and connective tissue disorders
Joint range of motion decreased
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal and connective tissue disorder - Other, specify : body aches
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Nervous system disorders
Dizziness
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Nervous system disorders
Headache
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Nervous system disorders
Memory impairment
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
40.0%
2/5 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Nervous system disorders
Presyncope
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Nervous system disorders
Seizure
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Nervous system disorders
Tremor
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Psychiatric disorders
Confusion
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Psychiatric disorders
Delirium
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Psychiatric disorders
Depression
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
66.7%
2/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Psychiatric disorders
Hallucinations
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Psychiatric disorders
Insomnia
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
2/6 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Renal and urinary disorders
Hematuria
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Renal and urinary disorders
Renal and urinary disorders - Other, specify : dysuria
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Renal and urinary disorders
Urinary incontinence
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Renal and urinary disorders
Urinary tract pain
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Renal and urinary disorders
Urine discoloration
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Reproductive system and breast disorders
Vaginal inflammation
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
40.0%
2/5 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
28.6%
2/7 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
1/2 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
2/4 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Hoarseness
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
14.3%
1/7 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
1/2 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Postnasal drip
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
50.0%
1/2 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Productive cough
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
40.0%
2/5 • Number of events 3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory, thoracic and mediastinal disorders - Other, specify : tachypnea: unspecified
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Sore throat
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Skin and subcutaneous tissue disorders
Rash acneiform
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
40.0%
2/5 • Number of events 2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, specify : Rash - unspecified
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, specify : eczematous dermatitis
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
20.0%
1/5 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, specify : rash: unspecified
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Skin and subcutaneous tissue disorders
Skin and subcutaneous tissue disorders - Other, specify : unspecified rash
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Vascular disorders
Hypertension
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/6 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/4 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
|
Vascular disorders
Hypotension
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
16.7%
1/6 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/5 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/3 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/7 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
0.00%
0/2 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
25.0%
1/4 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
33.3%
1/3 • Number of events 1 • Adverse events were recorded for 6 weeks, whereas serious adverse events were recorded for 1 year after the last EBV specific T cell infusion. All-cause mortality data were collected over a 5-year period.
Adverse events were collected as per protocol for participants who received EBV Specific T cell (EST) infusions.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place